Recordati : Recordati engrange de la confiance
>Une profitabilité plus solide que prévu au T3 - Recordati a publié hier ses chiffres au titre du T3 2023. Les ventes ressortent à 512 M€ (+1% vs css) en croissance de 5.5% yoy malgré un impact forex négatif de 29.6 M€ sur la période (-59.6 M€ sur les 9 1ers mois ; -4.6%), tirées par les business Specialty & Primary Care (plus de 10% de croissance au T3 hors effet changes) et les maladies rares (+23.5% depuis le début de l’année) avec notamment les franchises endo et ...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.